{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tolterodine+ER",
    "query": {
      "intervention": "Tolterodine ER"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tolterodine+ER&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T04:45:38.675Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03583372",
      "title": "An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Vibegron",
          "type": "DRUG"
        },
        {
          "name": "placebos",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine Tartrate ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 506,
      "start_date": "2018-06-14",
      "completion_date": "2019-07-25",
      "has_results": true,
      "last_update_posted_date": "2021-03-18",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 107,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 90 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03583372"
    },
    {
      "nct_id": "NCT01050114",
      "title": "OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "onaBoNT-A",
          "type": "DRUG"
        },
        {
          "name": "Oxybutynin ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Christopher Patrick Smith",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-08",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-30",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01050114"
    },
    {
      "nct_id": "NCT00413790",
      "title": "Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Darifenacin",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 162,
      "start_date": "2006-11",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2008-01-15",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 12,
      "location_summary": "Scottsdale, Arizona • Tempe, Arizona • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jupiter",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413790"
    },
    {
      "nct_id": "NCT01741454",
      "title": "Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ureteral Obstruction"
      ],
      "interventions": [
        {
          "name": "Tamsulosin",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 181,
      "start_date": "2012-11",
      "completion_date": "2018-03-30",
      "has_results": true,
      "last_update_posted_date": "2019-07-10",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01741454"
    },
    {
      "nct_id": "NCT00649259",
      "title": "Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Oxybutynin Chloride ER Tablets 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Ditropan XL® Tablets 10 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2002-10",
      "completion_date": "2002-11",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 1,
      "location_summary": "Morgantown, West Virginia",
      "locations": [
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00649259"
    },
    {
      "nct_id": "NCT03492281",
      "title": "A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "vibegron",
          "type": "DRUG"
        },
        {
          "name": "Vibegron placebo",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine Tartrate ER",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1530,
      "start_date": "2018-03-26",
      "completion_date": "2019-02-04",
      "has_results": true,
      "last_update_posted_date": "2021-03-04",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 191,
      "location_summary": "Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03492281"
    },
    {
      "nct_id": "NCT00611026",
      "title": "Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "Tolterodine ER",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Fesoterodine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2417,
      "start_date": "2008-02",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2011-02-02",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 102,
      "location_summary": "Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more",
      "locations": [
        {
          "city": "Enterprise",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611026"
    },
    {
      "nct_id": "NCT00444925",
      "title": "Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "fesoterodine fumarate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "tolterodine tartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1712,
      "start_date": "2007-04",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2015-03-24",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 41,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 36 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Orangevale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00444925"
    },
    {
      "nct_id": "NCT00939120",
      "title": "Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Benign Prostatic Hyperplasia (BPH)"
      ],
      "interventions": [
        {
          "name": "Tolterodine ER 4mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pre-randomization Dutasteride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Siami, Paul F., M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "50 Years and older · Male only"
      },
      "enrollment_count": 46,
      "start_date": "2009-07",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-05-01",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 1,
      "location_summary": "Newburgh, Indiana",
      "locations": [
        {
          "city": "Newburgh",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00939120"
    },
    {
      "nct_id": "NCT00688688",
      "title": "Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder, Overactive"
      ],
      "interventions": [
        {
          "name": "Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Tolterodine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Mirabegron",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Tolterodine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2792,
      "start_date": "2008-04-25",
      "completion_date": "2010-05-06",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-09-17T04:45:38.675Z",
      "location_count": 106,
      "location_summary": "Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00688688"
    }
  ]
}